Search Results

You are looking at 171 - 180 of 183 items for :

  • "tamoxifen" x
  • Refine by Access: All x
Clear All
Full access

Jessica K. DeMartino

,N0,M0, or stage II or III hormone receptor-negative breast cancer. NQF #0220: Tamoxifen or third-generation aromatase inhibitor is considered or administered within 1 year (365 days) of diagnosis for women with AJCC T1c,N0,M0, or stage II or III

Full access

Yuan-Yuan Lei, Suzanne C. Ho, Ashley Cheng, Carol Kwok, Chi-Kiu Iris Lee, Ka Li Cheung, Roselle Lee, Herbert H.F. Loong, Yi-Qian He, and Winnie Yeo

-conserving surgery, chemotherapy, radiation therapy, hormone therapy such as tamoxifen and aromatase inhibitors, and anti-HER2 therapy). At baseline and 18-month follow-up, the self-reported total comorbidity counts included diabetes, hypertension, hyperlipidemia

Full access

Arti Hurria, Tanya Wildes, Sarah L. Blair, Ilene S. Browner, Harvey Jay Cohen, Mollie deShazo, Efrat Dotan, Barish H. Edil, Martine Extermann, Apar Kishor P. Ganti, Holly M. Holmes, Reshma Jagsi, Mohana B. Karlekar, Nancy L. Keating, Beatriz Korc-Grodzicki, June M. McKoy, Bruno C. Medeiros, Ewa Mrozek, Tracey O’Connor, Hope S. Rugo, Randall W. Rupper, Rebecca A. Silliman, Derek L. Stirewalt, William P. Tew, Louise C. Walter, Alva B. Weir III, Mary Anne Bergman, and Hema Sundar

and nonadherence to adjuvant hormonal therapy in a cohort of 8,769 early-stage breast cancer patients . J Clin Oncol 2010 ; 28 : 4120 – 4128 . 218. Demissie S Silliman RA Lash TL . Adjuvant tamoxifen: predictors of use, side effects, and

Full access

Yvonne Bombard, Peter B. Bach, and Kenneth Offit

tamoxifen-treated, node-negative breast cancer . N Engl J Med 2004 ; 351 : 2817 – 2826 . 9. 9. Paik S Tang G Shak S . Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer . J Clin

Full access

services. AB2014.13. CAPTURE (Compliance and Preference for Tamoxifen Registry) Patient Survey Reveals Potential Strategies to Improve Long-Term Adherence to TAM Based on Choice: Results of a Large Internet-Based Survey Stefan Glück, MD a ; Jivesh

Full access

Alan P. Venook, Maria E. Arcila, Al B. Benson III, Donald A. Berry, David Ross Camidge, Robert W. Carlson, Toni K. Choueiri, Valerie Guild, Gregory P. Kalemkerian, Razelle Kurzrock, Christine M. Lovly, Amy E. McKee, Robert J. Morgan, Anthony J. Olszanski, Mary W. Redman, Vered Stearns, Joan McClure, and Marian L. Birkeland

and timing of tamoxifen in postmenopausal patients with endocrine-responsive, node-positive breast cancer: a phase 3, open-label, randomised controlled trial . Lancet 2009 ; 374 : 2055 – 2063 . 16. Guidance for industry: pathologic

Full access

Therese B. Bevers, Benjamin O. Anderson, Ermelinda Bonaccio, Sandra Buys, Mary B. Daly, Peter J. Dempsey, William B. Farrar, Irving Fleming, Judy E. Garber, Randall E. Harris, Alexandra S. Heerdt, Mark Helvie, John G. Huff, Nazanin Khakpour, Seema A. Khan, Helen Krontiras, Gary Lyman, Elizabeth Rafferty, Sara Shaw, Mary Lou Smith, Theodore N. Tsangaris, Cheryl Williams, and Thomas Yankeelov

Trial of tamoxifen versus placebo and the Study of Tamoxifen and Raloxifene (STAR) trial. The modified Gail model risk assessment tool also provides an estimate of a woman's lifetime risk for developing breast cancer. However, this estimate is based on

Full access

Robert J. Morgan Jr, Deborah K. Armstrong, Ronald D. Alvarez, Jamie N. Bakkum-Gamez, Kian Behbakht, Lee-may Chen, Larry Copeland, Marta Ann Crispens, Maria DeRosa, Oliver Dorigo, David M. Gershenson, Heidi J. Gray, Ardeshir Hakam, Laura J. Havrilesky, Carolyn Johnston, Shashikant Lele, Lainie Martin, Ursula A. Matulonis, David M. O'Malley, Richard T. Penson, Sanja Percac-Lima, Mario Pineda, Steven C. Plaxe, Matthew A. Powell, Elena Ratner, Steven W. Remmenga, Peter G. Rose, Paul Sabbatini, Joseph T. Santoso, Theresa L. Werner, Jennifer Burns, and Miranda Hughes

paclitaxel or docetaxel; (2) observation (category 2B); or (3) hormone therapy including anastrozole, letrozole, leuprolide, or tamoxifen (category 2B for all hormone therapy). Postoperative options for patients with stage III to IV disease include (1) first

Full access

Priscilla K. Brastianos, William T. Curry, and Kevin S. Oh

breast cancer with tamoxifen. Report of three cases . Tumori 1993 ; 79 : 359 – 362 . 84. Madhup R Kirti S Bhatt ML . Letrozole for brain and scalp metastases from breast cancer—a case report . Breast 2006 ; 15 : 440 – 442 . 85

Full access

Edward E. Partridge, Nadeem R. Abu-Rustum, Susan M. Campos, Patrick J. Fahey, Michael Farmer, Rochelle L. Garcia, Anna Giuliano, Howard W. Jones III, Subodh M. Lele, Richard W. Lieberman, Stewart L. Massad, Mark A. Morgan, R. Kevin Reynolds, Helen E. Rhodes, Diljeet K. Singh, Karen Smith-McCune, Nelson Teng, Cornelia Liu Trimble, Fidel Valea, and Sharon Wilczynski

, tamoxifen therapy, anovulation, or hereditary nonpolyposis cancer syndrome (HNPCC). Patients aged 35 years or older and all those with atypical glandular endometrial cells, abnormal bleeding, or endometrial cancer risk factors should also undergo